{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:26:26Z","timestamp":1791584786344,"version":"4.3.4"},"reference-count":90,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of vascular death after heart attack and stroke. Anticoagulation therapy is the cornerstone of VTE treatment. Despite such therapy, up to 50% of patients with DVT develop postthrombotic syndrome, and up to 4% of patients with PE develop chronic thromboembolic pulmonary hypertension. Therefore, better therapies are needed. Although direct oral anticoagulants are more convenient and safer than warfarin for VTE treatment, bleeding remains the major side effect, particularly in cancer patients. Factor XII and factor XI have emerged as targets for new anticoagulants that may be safer. To reduce the complications of VTE, attenuation of thrombin activatable fibrinolysis inhibitor activity is under investigation in PE patients to enhance endogenous fibrinolysis, whereas blockade of leukocyte interaction with the vessel wall is being studied to reduce the inflammation that contributes to postthrombotic syndrome in DVT patients. Focusing on these novel antithrombotic strategies, this article explains why safer anticoagulants are needed, provides the rationale for factor XII and XI as targets for such agents, reviews the data on the factor XII\u2013 and factor XI\u2013directed anticoagulants under development, describes novel therapies to enhance fibrinolysis and decrease inflammation in PE and DVT patients, respectively, and offers insights into the opportunities for these novel VTE therapies.<\/jats:p>","DOI":"10.1182\/blood.2019000919","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T09:49:50Z","timestamp":1578563390000},"page":"351-359","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":81,"title":["Novel antithrombotic strategies for treatment of venous thromboembolism"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-7550","authenticated-orcid":false,"given":"Jeffrey I.","family":"Weitz","sequence":"first","affiliation":[{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada; and Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9491-6172","authenticated-orcid":false,"given":"Noel C.","family":"Chan","sequence":"additional","affiliation":[{"name":"Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada; and Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23 suppl 1","key":"2020013012000127500_B1","first-page":"I4","article-title":"The epidemiology of venous thromboembolism","volume":"107","author":"White","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"2020013012000127500_B2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archinte.159.5.445","article-title":"Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study","volume":"159","author":"Heit","year":"1999","journal-title":"Arch Intern Med"},{"issue":"23 suppl 1","key":"2020013012000127500_B3","first-page":"I22","article-title":"Natural history of venous thromboembolism","volume":"107","author":"Kearon","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"2020013012000127500_B4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2009.07601.x","article-title":"Post-thrombotic syndrome: prevalence, prognostication and need for progress","volume":"145","author":"Prandoni","year":"2009","journal-title":"Br J Haematol"},{"key":"2020013012000127500_B5","doi-asserted-by":"crossref","first-page":"985","DOI":"10.12688\/f1000research.11174.1","article-title":"Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants","volume":"6","author":"Weitz","year":"2017","journal-title":"F1000 Res"},{"issue":"9","key":"2020013012000127500_B6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1161\/CIRCRESAHA.116.306925","article-title":"Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants","volume":"118","author":"Chan","year":"2016","journal-title":"Circ Res"},{"issue":"12","key":"2020013012000127500_B7","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2020013012000127500_B8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report [published correction appears in Chest. 2016;150(4):988]","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"9","key":"2020013012000127500_B9","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2020013012000127500_B10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"},{"issue":"1","key":"2020013012000127500_B11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/ATVBAHA.118.310960","article-title":"Advances in antithrombotic therapy","volume":"39","author":"Weitz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"2020013012000127500_B12","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa1615066","article-title":"Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis","volume":"377","author":"Vedantham","year":"2017","journal-title":"N Engl J Med"},{"issue":"9810","key":"2020013012000127500_B13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)61753-4","article-title":"Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial","volume":"379","author":"Enden","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"2020013012000127500_B14","doi-asserted-by":"crossref","first-page":"e004345","DOI":"10.1161\/CIRCINTERVENTIONS.116.004345","article-title":"Interventional treatment of pulmonary embolism","volume":"10","author":"Dudzinski","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"2020013012000127500_B15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01062714","article-title":"Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial","volume":"2","author":"Jerjes-Sanchez","year":"1995","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"2020013012000127500_B16","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1378\/chest.08-2988","article-title":"Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure","volume":"136","author":"Kline","year":"2009","journal-title":"Chest"},{"issue":"2","key":"2020013012000127500_B17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.amjcard.2012.09.027","article-title":"Moderate pulmonary embolism treated with thrombolysis (from the \u201cMOPETT\u201d Trial)","volume":"111","author":"Sharifi","year":"2013","journal-title":"Am J Cardiol"},{"issue":"23","key":"2020013012000127500_B18","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2014.5990","article-title":"Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis","volume":"311","author":"Chatterjee","year":"2014","journal-title":"JAMA"},{"issue":"15","key":"2020013012000127500_B19","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa1302097","article-title":"Fibrinolysis for patients with intermediate-risk pulmonary embolism","volume":"370","author":"Meyer","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2020013012000127500_B20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/ATVBAHA.108.162289","article-title":"Mechanisms of venous thrombosis and resolution","volume":"28","author":"Wakefield","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"2020013012000127500_B21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/blood-2016-05-718114","article-title":"The role of leukocytes in thrombosis","volume":"128","author":"Swystun","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2020013012000127500_B22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/cvr\/cvv154","article-title":"Selectins: initiators of leucocyte adhesion and signalling at the vascular wall","volume":"107","author":"McEver","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"4","key":"2020013012000127500_B23","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/j.thromres.2009.10.022","article-title":"P-selectin\/PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis","volume":"125","author":"Ramacciotti","year":"2010","journal-title":"Thromb Res"},{"issue":"7","key":"2020013012000127500_B24","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"2020013012000127500_B25","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2020013012000127500_B26","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S0049-3848(16)30363-2","article-title":"Factor XI and factor XII as targets for new anticoagulants","volume":"141","author":"Weitz","year":"2016","journal-title":"Thromb Res"},{"issue":"6","key":"2020013012000127500_B27","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1538-7836.2007.02446.x","article-title":"The intrinsic pathway of coagulation: a target for treating thromboembolic disease?","volume":"5","author":"Gailani","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2020013012000127500_B28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1160\/TH12-11-0803","article-title":"Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway?","volume":"110","author":"van Montfoort","year":"2013","journal-title":"Thromb Haemost"},{"issue":"3","key":"2020013012000127500_B29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12975-012-0186-5","article-title":"Inhibition of factor XII-mediated activation of factor XI provides protection against experimental acute ischemic stroke in mice","volume":"3","author":"Leung","year":"2012","journal-title":"Transl Stroke Res"},{"issue":"2","key":"2020013012000127500_B30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.20050664","article-title":"Defective thrombus formation in mice lacking coagulation factor XII","volume":"202","author":"Renn\u00e9","year":"2005","journal-title":"J Exp Med"},{"issue":"Suppl 1","key":"2020013012000127500_B31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1538-7836.2009.03393.x","article-title":"Factor XI deficiency in animal models","volume":"7","author":"Renn\u00e9","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"19","key":"2020013012000127500_B32","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1182\/blood-2011-05-355248","article-title":"Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding","volume":"118","author":"Revenko","year":"2011","journal-title":"Blood"},{"issue":"22","key":"2020013012000127500_B33","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2020013012000127500_B34","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","article-title":"Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates [published corrections appear in Arterioscler Thromb Vasc Biol. 2013;33(8):e127 and 2013;33(10):e130]","volume":"33","author":"Crosby","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"2020013012000127500_B35","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1182\/blood.V128.22.3766.3766","article-title":"Bleeding in factor XI deficient mice","volume":"128","author":"Ay","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2020013012000127500_B36","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1182\/blood.V124.21.4219.4219","article-title":"Clots from FXI-deficient patients display a reduced fibrinolytic resistance","volume":"124","author":"Peyvandi","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2020013012000127500_B37","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/jth.13342","article-title":"Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway","volume":"14","author":"Colucci","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2020013012000127500_B38","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/asheducation-2014.1.66","article-title":"Epidemiologic and clinical data linking factors XI and XII to thrombosis","volume":"2014","author":"Key","year":"2014","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"11","key":"2020013012000127500_B39","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","article-title":"Factor XII inhibition reduces thrombus formation in a primate thrombosis model","volume":"123","author":"Matafonov","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020013012000127500_B40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/ATVBAHA.119.312459","article-title":"AB023, a novel antibody that binds factor XI and blocks its activation by factor XIIa","volume":"39","author":"Chan","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2020013012000127500_B41","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2020013012000127500_B42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: first evaluation of safety, pharmacodynamics, and pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"13","key":"2020013012000127500_B43","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"2020013012000127500_B44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.thromres.2017.06.015","article-title":"Generation and characterization of aptamers targeting factor XIa","volume":"156","author":"Woodruff","year":"2017","journal-title":"Thromb Res"},{"key":"2020013012000127500_B45","unstructured":"ClinicalTrials.gov\n          . A study of JNJ-70033093 (BMS-986177) versus subcutaneous enoxaparin in participants undergoing elective total knee replacement surgery. Identifier NCT03891524. https:\/\/ClinicalTrials.gov\/show\/NCT03891524. Accessed 24 May 2019."},{"issue":"suppl 1","key":"2020013012000127500_B46","first-page":"A13747","article-title":"Phase 1a\/1b study of EP-7041: a novel, potent, selective, small molecule FXIa inhibitor","volume":"136","author":"Hayward","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"2020013012000127500_B47","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1261\/rna.068916.118","article-title":"An investigational RNAi therapeutic targeting factor XII (ALN-F12) for the treatment of hereditary angioedema","volume":"25","author":"Liu","year":"2019","journal-title":"RNA"},{"issue":"13","key":"2020013012000127500_B48","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2020013012000127500_B49","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/jth.12302","article-title":"Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer","volume":"11","author":"Woodruff","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2020013012000127500_B50","first-page":"236","article-title":"The anti-factor XII antibody AB052 is antithrombotic without hemostatic impairment in a primate model of extracorporeal membrane oxygenation","volume":"130","author":"Wallisch","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2020013012000127500_B51","first-page":"247","article-title":"The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities","volume":"3","author":"Worm","year":"2015","journal-title":"Ann Transl Med"},{"issue":"4","key":"2020013012000127500_B52","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.jaci.2018.06.014","article-title":"Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation","volume":"142","author":"Cao","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2020013012000127500_B53","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2020013012000127500_B54","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/bloodadvances.2018016337","article-title":"Structures of human plasma \u03b2-factor XIIa cocrystallized with potent inhibitors","volume":"2","author":"Dementiev","year":"2018","journal-title":"Blood Adv"},{"key":"2020013012000127500_B55","unstructured":"ClinicalTrials.gov\n          . FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty (FOXTROT). Identifier NCT03276143. https:\/\/ClinicalTrials.gov\/show\/NCT03276143. Accessed 24 May 2019."},{"key":"2020013012000127500_B56","unstructured":"ClinicalTrials.gov\n          . A study of safety, PK, & PD of ISIS 416858 administered subcutaneously to patients with end-stage renal disease on hemodialysis. Identifier NCT02553889. https:\/\/ClinicalTrials.gov\/show\/NCT02553889. Accessed 24 May 2019."},{"key":"2020013012000127500_B57","unstructured":"ClinicalTrials.gov\n          . A study of ISIS 416858 administered subcutaneously to patients with end-stage renal disease on hemodialysis. Identifier NCT03358030. https:\/\/ClinicalTrials.gov\/show\/NCT03358030. Accessed 24 May 2019."},{"issue":"suppl 1","key":"2020013012000127500_B58","first-page":"1116","article-title":"Pharmacokinetics and pharmacodynamics of Ionis-FXIRx, an antisense inhibitor of factor XI, in patients with end-stage renal disease on hemodialysis","volume":"130","author":"Bethune","year":"2017","journal-title":"Blood"},{"key":"2020013012000127500_B59","unstructured":"ClinicalTrials.gov\n          . An investigational study to assess the effect of BMS-986177 on aspirin in healthy participants. Identifier NCT03341390. https:\/\/ClinicalTrials.gov\/show\/NCT03341390. Accessed 24 May 2019."},{"key":"2020013012000127500_B60","unstructured":"ClinicalTrials.gov\n          . Safety and tolerability study of BMS-986177 in healthy subjects. Identifier NCT02608970. https:\/\/ClinicalTrials.gov\/show\/NCT02608970. Accessed 24 May 2019."},{"key":"2020013012000127500_B61","unstructured":"ClinicalTrials.gov\n          . Oral factor XIa inhibitor for the prevention of new ischemic stroke in patients receiving aspirin and clopidogrel following acute ischemic stroke or transient ischemic attack (TIA). Identifier NCT03766581. https:\/\/ClinicalTrials.gov\/show\/NCT03766581. Accessed 24 May 2019."},{"issue":"11","key":"2020013012000127500_B62","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/CIRCULATIONAHA.110.961136","article-title":"Management of submassive pulmonary embolism","volume":"122","author":"Piazza","year":"2010","journal-title":"Circulation"},{"issue":"14","key":"2020013012000127500_B63","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1182\/blood-2014-08-559278","article-title":"The role of thrombolytic therapy in pulmonary embolism","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2020013012000127500_B64","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1097\/CCM.0000000000003288","article-title":"Half-dose versus full-dose alteplase for treatment of pulmonary embolism","volume":"46","author":"Kiser","year":"2018","journal-title":"Crit Care Med"},{"issue":"10","key":"2020013012000127500_B65","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/jth.14215","article-title":"Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke","volume":"16","author":"Henderson","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"42","key":"2020013012000127500_B66","doi-asserted-by":"crossref","first-page":"27176","DOI":"10.1074\/jbc.273.42.27176","article-title":"A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor","volume":"273","author":"Wang","year":"1998","journal-title":"J Biol Chem"},{"issue":"5","key":"2020013012000127500_B67","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/jth.13658","article-title":"A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects","volume":"15","author":"Zhou","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2020013012000127500_B68","unstructured":"ClinicalTrials.gov\n          . Randomized study to assess the safety, pharmacokinetics\/dynamics of DS-1040b in subjects with acute submassive pulmonary embolism. Identifier NCT02923115. https:\/\/ClinicalTrials.gov\/show\/NCT02923115. Accessed 24 May 2019."},{"issue":"9","key":"2020013012000127500_B69","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/j.1538-7836.2008.03056.x","article-title":"Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation","volume":"6","author":"Mosesson","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2020013012000127500_B70","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1161\/01.CIR.95.7.1886","article-title":"Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism","volume":"95","author":"Butte","year":"1997","journal-title":"Circulation"},{"issue":"5","key":"2020013012000127500_B71","doi-asserted-by":"crossref","first-page":"e0196911","DOI":"10.1371\/journal.pone.0196911","article-title":"Generation and characterization of monoclonal antibodies against the N-terminus of alpha-2-antiplasmin","volume":"13","author":"Abdul","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"2020013012000127500_B72","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/hyb.1997.16.281","article-title":"Functional characterization of monoclonal antibody inhibitors of alpha 2-antiplasmin that accelerate fibrinolysis in different animal plasmas","volume":"16","author":"Reed","year":"1997","journal-title":"Hybridoma"},{"issue":"suppl 1","key":"2020013012000127500_B73","first-page":"A14994","article-title":"Inactivation of \u03b12-antiplasmin promotes thrombus dissolution in humans: preliminary results of the Novel \u03b12-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial","volume":"134","author":"Reed","year":"2016","journal-title":"Circulation"},{"issue":"21","key":"2020013012000127500_B74","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1182\/blood-2009-07-199174","article-title":"How I treat postthrombotic syndrome","volume":"114","author":"Kahn","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2020013012000127500_B75","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1538-7836.2004.01106.x","article-title":"Vein abnormalities and the post-thrombotic syndrome","volume":"3","author":"Prandoni","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2020013012000127500_B76","first-page":"825","article-title":"The post-thrombotic syndrome: incidence and prognostic value of non-invasive venous examinations in a six-year follow-up study","volume":"94","author":"Roumen-Klappe","year":"2005","journal-title":"Thromb Haemost"},{"issue":"9920","key":"2020013012000127500_B77","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(13)61902-9","article-title":"Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"2020013012000127500_B78","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"von Br\u00fchl","year":"2012","journal-title":"J Exp Med"},{"issue":"11","key":"2020013012000127500_B79","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2008-01-078204","article-title":"The vessel wall and its interactions","volume":"111","author":"Wagner","year":"2008","journal-title":"Blood"},{"issue":"21","key":"2020013012000127500_B80","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/blood.V124.21.593.593","article-title":"E-selectin inhibitor GMI-1271 works in combination with low-molecular weight heparin to decrease venous thrombosis and bleeding risk in a mouse model","volume":"124","author":"Myers","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2020013012000127500_B81","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1160\/TH16-04-0323","article-title":"E-selectin inhibition with GMI-1271 decreases venous thrombosis without profoundly affecting tail vein bleeding in a mouse model","volume":"117","author":"Culmer","year":"2017","journal-title":"Thromb Haemost"},{"key":"2020013012000127500_B82","unstructured":"ClinicalTrials.gov\n          . Study to assess the safety and efficacy of SelK2 to prevent blood clots in patients undergoing total knee replacement (COURSE). Identifier NCT03812328. https:\/\/ClinicalTrials.gov\/show\/NCT03812328. Accessed 24 May 2019."},{"issue":"2","key":"2020013012000127500_B83","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jvsv.2019.01.011","article-title":"E-selectin inhibition: a new way to treat proximal deep venous thrombosis","volume":"7","author":"Myers","year":"2019","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"23","key":"2020013012000127500_B84","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood.V126.23.1004.1004","article-title":"First in human phase 1 single dose escalation studies of the e-selectin antagonist GMI-1271 show a favorable safety, pharmacokinetic, and biomarker profile","volume":"126","author":"Devata","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2020013012000127500_B85","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1182\/blood.V128.22.3826.3826","article-title":"E-selectin antagonist GMI-1271 shows a favorable safety, PK and bleeding profile in phase I studies of healthy volunteers","volume":"128","author":"Angelini","year":"2016","journal-title":"Blood"},{"key":"2020013012000127500_B86","unstructured":"ClinicalTrials.gov\n          . Study to assess safety, tolerability, and efficacy of GMI-1271 in patients with calf-level deep venous thrombosis (DVT). Identifier NCT02744833. https:\/\/ClinicalTrials.gov\/show\/NCT02744833. Accessed 24 May 2019."},{"issue":"5","key":"2020013012000127500_B87","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/nat.2014.0490","article-title":"Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeutics","volume":"24","author":"Cavagnaro","year":"2014","journal-title":"Nucleic Acid Ther"},{"issue":"13","key":"2020013012000127500_B88","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2020013012000127500_B89","doi-asserted-by":"crossref","first-page":"e002322","DOI":"10.1161\/JAHA.115.002322","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"2020013012000127500_B90","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.actbio.2012.07.019","article-title":"Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo","volume":"8","author":"Yau","year":"2012","journal-title":"Acta Biomater"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/5\/351\/1632849\/bloodbld2019000919c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/5\/351\/1632849\/bloodbld2019000919c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T12:01:45Z","timestamp":1580385705000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/5\/351\/430067\/Novel-antithrombotic-strategies-for-treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,1,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000919","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}